Persistent Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Following Virus Eradication After Direct-Acting Antiviral Therapy

Hepatology - United States
doi 10.1002/hep.28981
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Daclatasvir/Asunaprevir Based Direct-Acting Antiviral Therapy Ameliorate Hepatitis C Virus-Associated Cryoglobulinemic Membranoproliferative Glomerulonephritis: A Case Report

BMC Nephrology
Nephrology
2017English

Predictors of Hepatocellular Carcinoma After Hepatitis C Virus Eradication Following Direct-Acting Antiviral Treatment: Relationship With Serum Zinc

Journal of Clinical Biochemistry and Nutrition
MedicineNutritionClinical BiochemistryDietetics
2020English

Short-Term Risk of Hepatocellular Carcinoma After Hepatitis C Virus Eradication Following Direct-Acting Anti-Viral Treatment

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Direct-Acting Antiviral Drugs and Hepatitis C Virus: A Therapeutic Revolution?

Cancer
Cancer ResearchOncology
2015English

Oral Direct-Acting Antiviral Therapy for Hepatitis C

Journal of Antivirals & Antiretrovirals
2012English

Response To: Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antiviral Drug

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2016English

Clinical Outcomes of Direct-Acting Antiviral Therapy in Patients With Compensated Hepatitis C Virus-Related Cirrhosis

Hepatoma Research
2017English

Two Cases of Hepatocellular Carcinoma Occurring Immediately After Direct-Acting Antiviral Agents Against Hepatitis C Virus

Internal Medicine
Internal MedicineMedicine
2019English

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents

PLoS Pathogens
ImmunologyMolecular BiologyVirologyMicrobiologyParasitologyGenetics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy